Skip to content

Study · Animal study (in vivo) · mouse · 1997

5 results

Role of melanocortinergic neurons in feeding and the agouti obesity syndrome.

Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD

Nature1 Jan 1997Cited by 1,362 (Europe PMC)

PMID8990120 (opens in a new tab)DOI10.1038/385165a0 (opens in a new tab)PepBankPUB-08990120
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In fasted C57BL/6J mice, intracerebroventricular MTII inhibited feeding.

    In plain wordsIn fasted mice, MTII given into the brain reduced feeding.

    Peptide
    Melanotan II
    Outcome
    DecreaseFeeding in fasted C57BL/6J mice
    Study

    mousen: not reported in source

    Fasted C57BL/6J mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Intracerebroventricular administration of the agonist, MTII, inhibited feeding in four models of hyperphagia: fasted C57BL/6J, ob/ob, and A(Y) mice, and mice injected with neuropeptide Y.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ob/ob mice, intracerebroventricular MTII inhibited feeding.

    In plain wordsIn obese ob/ob mice, MTII given into the brain reduced feeding.

    Peptide
    Melanotan II
    Outcome
    DecreaseFeeding in ob/ob mice
    Study

    mousen: not reported in source

    ob/ob mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Intracerebroventricular administration of the agonist, MTII, inhibited feeding in four models of hyperphagia: fasted C57BL/6J, ob/ob, and A(Y) mice, and mice injected with neuropeptide Y.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In A(Y) mice, intracerebroventricular MTII inhibited feeding.

    In plain wordsIn A(Y) mice, MTII given into the brain reduced feeding.

    Peptide
    Melanotan II
    Outcome
    DecreaseFeeding in A(Y) mice
    Study

    mousen: not reported in source

    A(Y) mice
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Intracerebroventricular administration of the agonist, MTII, inhibited feeding in four models of hyperphagia: fasted C57BL/6J, ob/ob, and A(Y) mice, and mice injected with neuropeptide Y.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In mice injected with neuropeptide Y, intracerebroventricular MTII inhibited feeding.

    In plain wordsIn mice given neuropeptide Y, MTII given into the brain reduced feeding.

    Peptide
    Melanotan II
    Outcome
    DecreaseFeeding in mice injected with neuropeptide Y
    Study

    mousen: not reported in source

    Mice injected with neuropeptide Y
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (mouse).

    Source sentences

    Summary
    Intracerebroventricular administration of the agonist, MTII, inhibited feeding in four models of hyperphagia: fasted C57BL/6J, ob/ob, and A(Y) mice, and mice injected with neuropeptide Y.

Studies that did not test the peptide alone1

In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Melanotan II.

  1. 05AnimalNot a test of Melanotan II aloneAnimal study (in vivo)Mechanism

    In mice, co-administration of the antagonist SHU9119 completely blocked the inhibition of feeding caused by MTII.

    In plain wordsIn mice, the blocker SHU9119 completely stopped MTII from reducing feeding.

    Peptide
    Melanotan II
    Outcome
    Not applicableBlockade of MTII-induced feeding inhibition by SHU9119
    Study

    mousen: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    Co-administration of the specific melanocortin antagonist and agouti-mimetic SHU9119 completely blocked this inhibition.

    In this study, Melanotan II was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Melanotan II.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.